NCT07143240

Tedizolid Neuropathies

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 5 (actual)
• Sponsor: Hospices Civils de Lyon · Academic / Other
• Sex: All
• Age: —
• Healthy volunteers: —

Summary

Tedizolid is a new oxazolidinone, related to linezolid. It has obtained marketing authorization for the treatment of skin and soft tissue infections. Its potential interest compared to linezolid lies mainly in its better tolerance in the context of more prolonged treatments required in chronic Gram-positive cocci infections such as osteoarticular infections. Indeed, linezolid has hematological toxicity, appearing beyond 10 days of treatment. Due to a lower dosage and lower mitochondrial toxicity, the hematological tolerance of tedizolid is better, even allowing it to be used as a relay from linezolid after the occurrence of hematotoxicity. Another side effect of the oxazolidinone class is the occurrence of optic and peripheral neuropathies observed under linezolid. The pharmacological properties of tedizolid and in vitro and in vivo data suggested a lower risk of neurotoxicity, although a few cases have been published..

Conditions

• Adult Patients Developing Optic or Peripheral Neuropathy
• While Receiving Tedizolid Therapy Between July 2019 and December 2024

Interventions

Type	Name	Description
OTHER	Determine patient demographic and clinical characteristics at baseline	Description of demographic data (sex, age), comorbidities (Charlson scores), septic history, clinical data relating to neuropathy, and tedizolid prescription modalities (dose, duration).

Timeline

• Start date: 2025-03-01
• Primary completion: 2025-04-01
• Completion: 2025-05-01
• First posted: 2025-08-27
• Last updated: 2025-08-27

Locations

1 site across 1 country: France